KRKNF yields 34.78% · PFE yields 6.13%● Live data
📍 KRKNF pulled ahead of the other in Year 1
Combined, KRKNF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KRKNF + PFE for your $10,000?
Kraken Robotics Inc., a marine technology company, engages in the design, manufacture, and sale of software-centric sensors, batteries, and underwater robotic systems for unmanned underwater vehicles used in military and commercial applications. It operates in two segments, Sensors and Platforms, and Power. The company offers AquaPix Miniature interferometric synthetic aperture sonar (MINSAS), a configurable MINSAS; and SeaVision, an underwater laser imaging system. It also provides Kraken Active Towed Fish (KATFISH), a towed underwater vehicle for high speed and high resolution seabed mapping; ThunderFish, an autonomous underwater vehicle; and ALARS, an autonomous launch and recovery system that enable an unmanned vehicle and its payloads to be brought aboard to a host ship. In addition, the company designs and manufactures pressure tolerant thrusters, drives, batteries, battery management systems, and electronics; and robotics as a service, as well as implements digital signal processing and user interface software for anti-submarine warfare sonar applications. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Kraken Sonar Inc. and changed its name to Kraken Robotics Inc. in September 2017. Kraken Robotics Inc. is headquartered in Mount Pearl, Canada.
Full KRKNF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.